Although current prognostic biomarkers (e.g., FLT3-ITD, NPM1 mutations, etc.)have been helpful in risk-stratifying patients with AML, these molecular biomarkers remain somewhat unsatisfactory for accurately predicting clinical outcomes for a subset of patients with AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.